DOCSLIB.ORG

Weight Gain During Pregnancy: Reexamining the Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Weight Gain During Pregnancy: Reexamining the Guidelines Kathleen M. Rasmussen and Ann L. Yaktine, Editors Committee to Reexamine IOM Pregnancy Weight Guidelines Food and Nutrition Board and Board on Children, Youth, and Families PREPUBLICATION COPY: UNCORRECTED PROOFS THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This study was supported by Contract No. HHSH250200446009I TO HHSH240G5806 between the National Academy of Sciences and U.S. Department of Health and Human Services Health Resources and Services Administration; Contract No. 200-2007-M-21619 between the National Academy of Sciences and Centers for Disease Control and Prevention Division of Nutrition and Physical Activity and Obesity; Contract No. N01-OD-4-2139 TO 192 between the National Academy of Sciences and National Institutes of Health Institute of Child Health and Human Development; Contract No. N01-OD-4-2139 TO 192 between the National Academy of Sciences and National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Contract No. HHSP23300700522P between the National Academy of Sciences and U.S. Department of Health and Human Services Office on Women’s Health; Contract No. HHSP23320070071P between the National Academy of Sciences and U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion; and Contract No. 21- FY07-576 between the National Academy of Sciences and March of Dimes. Additional support came from U.S. Department of Health and Human Services Office of Minority Health and the National Minority AIDS Council. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project. International Standard Book Number 0-309-XXXXX-X (Book) International Standard Book Number 0-309- XXXXX -X (PDF) Library of Congress Control Number: 00 XXXXXX Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu. For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu. Copyright 2009 by the National Academy of Sciences. All rights reserved. Printed in the United States of America. The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin. Suggested citation: IOM (Institute of Medicine). 2009. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press. PREPUBLICATION COPY: UNCORRECTED PROOFS PREPUBLICATION COPY: UNCORRECTED PROOFS The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences. The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles M. Vest is president of the National Academy of Engineering. The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine. The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of the National Research Council. www.national-academies.org PREPUBLICATION COPY: UNCORRECTED PROOFS COMMITTEE ON THE REEXAMINATION OF IOM PREGNANCY WEIGHT GUIDELINES KATHLEEN M. RASMUSSEN (Chair), Professor of Nutrition, Division of Nutritional Sciences, Cornell University, Ithaca, NY BARBARA ABRAMS, Professor, School of Public Health, University of California–Berkeley LISA M. BODNAR, Assistant Professor, Department of Epidemiology, University of Pittsburgh, PA CLAUDE BOUCHARD, Executive Director and George A. Bray Chair in Nutrition, Pennington Biomedical Research Center, Baton Rouge, LA NANCY BUTTE, Professor of Pediatrics, Baylor College of Medicine, Houston, TX PATRICK M. CATALANO, Chair, Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, OH MATTHEW GILLMAN, Professor, Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA FERNANDO A. GUERRA, Director of Health, San Antonio Metropolitan Health District, TX PAULA A. JOHNSON, Executive Director, Connors Center for Women’s Health and Gender Biology, Chief, Division of Women’s Health, Brigham and Women’s Hospital, Boston, MA MICHAEL C. LU, Associate Professor of Obstetrics, Gynecology, and Public Health, Schools of Medicine and Public Health, University of California–Los Angeles ELIZABETH R. McANARNEY, Professor and Chair Emerita, Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, NY RAFAEL PEREZ-ESCAMILLA, Professor of Nutritional Sciences & Public Health, Director, NIH EXPORT Center for Eliminating Health Disparities among Latinos, University of Connecticut, Storrs DAVID A. SAVITZ, Charles W. Bluhdorn Professor of Community & Preventive Medicine, Director, Epidemiology, Biostatistics, and Disease Prevention Institute, Mount Sinai School of Medicine, New York, NY ANNA MARIA SIEGA-RIZ, Associate Professor, Department of Epidemiology, School of Public Health, University of North Carolina–Chapel Hill Study Staff ANN L. YAKTINE, Senior Program Officer HEATHER B. DEL VALLE, Research Associate M. JENNIFER DATILES, Senior Program Assistant ANTON BANDY, Financial Officer GERALDINE KENNEDO, Administrative Assistant LINDA D. MEYERS, Food and Nutrition Board Director ROSEMARY CHALK, Director, Board on Children, Youth, and Families PREPUBLICATION COPY: UNCORRECTED PROOFS v PREPUBLICATION COPY: UNCORRECTED PROOFS vi Reviewers This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council's (NRC’s) Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following individuals for their review of this report: Haywood Brown, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC Cutberto Garza, Boston College, MA Susan Gennaro, William F. Connell School of Nursing, Boston College, MA William Goodnight, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina–Chapel Hill School of Medicine Erica P. Gunderson, Division of Research, Kaiser Permanente, Oakland, CA Maxine Hayes, Department of Health, State of Washington, Tumwater Lorraine V. Klerman, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA Kristine G. Koski, School of Dietetics and Human Nutrition,
Recommended publications
  • Genes in Eyecare Geneseyedoc 3 W.M

    Genes in Eyecare Geneseyedoc 3 W.M

    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
  • Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulphonylurea-Sensitive Diabetes

    Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulphonylurea-Sensitive Diabetes

    Diabetes Care 1 Shivani Misra,1 Neelam Hassanali,2 Homozygous Hypomorphic Amanda J. Bennett,2 Agata Juszczak,2 Richard Caswell,3 Kevin Colclough,3 HNF1A Alleles Are a Novel Cause Jonathan Valabhji,4 Sian Ellard,3 of Young-Onset Diabetes and Nicholas S. Oliver,1,4 and Anna L. Gloyn2,5,6 Result in Sulphonylurea-Sensitive Diabetes https://doi.org/10.2337/dc19-1843 OBJECTIVE Heterozygous loss-of-function mutations in HNF1A cause maturity-onset diabetes of the young (MODY). Affected individuals can be treated with low-dose sulpho- nylureas. Individuals with homozygous HNF1A mutations causing MODY have not been reported. RESEARCH DESIGN AND METHODS We phenotyped a kindred with young-onset diabetes and performed molecular genetic testing, a mixed meal tolerance test, a sulphonylurea challenge, and in vitro assays to assess variant protein function. RESULTS A homozygous HNF1A variant (p.A251T) was identified in three insulin-treated 1 family members diagnosed with diabetes before 20 years of age. Those with the Diabetes, Endocrinology and Metabolism, Im- NOVEL COMMUNICATIONS IN DIABETES homozygous variant had low hs-CRP levels (0.2–0.8 mg/L), and those tested dem- perial College London, London, U.K. 2Oxford Centre for Diabetes, Endocrinology and onstrated sensitivity to sulphonylurea given at a low dose, completely transitioning off Metabolism, University of Oxford, Oxford, U.K. insulin. In silico modeling predicted a variant of unknown significance; however, in vitro 3Institute of Biomedical and Clinical Science, Uni- studies supported a modest reduction in transactivation potential (79% of that for the versity of Exeter Medical School, Exeter, U.K.
  • Two MODY 2 Families Identified in Brazilian Subjects

    Two MODY 2 Families Identified in Brazilian Subjects

    case report Incidental mild hyperglycemia in children: two MODY 2 families identified in Brazilian subjects Hiperglicemia incidental em crianças: duas famílias com MODY 2 identificadas em brasileiros Lílian A. Caetano1,2, Alexander A. L. Jorge1, Alexsandra C. Malaquias1, Ericka B. Trarbach1, Márcia S. Queiroz2, Márcia Nery2, Milena G. Teles1,2 SUMMARY Maturity-onset diabetes of the young (MODY) is characterized by an autosomal dominant mode 1 Unidade de Endocrinologia of inheritance, early onset of hyperglycemia, and defects of insulin secretion. MODY subtypes Genética e Laboratório de described present genetic, metabolic, and clinical differences. MODY 2 is characterized by mild Endocrinologia Molecular e Celular/LIM25, Disciplina de asymptomatic fasting hyperglycemia, and rarely requires pharmacological treatment. Hence, Endocrinologia, Faculdade precise diagnosis of MODY is important for determining management and prognosis. We report de Medicina da Universidade two heterozygous GCK mutations identified during the investigation of short stature. Case 1: a de São Paulo (FMUSP), São Paulo, SP, Brazil prepubertal 14-year-old boy was evaluated for constitutional delay of growth and puberty. During 2 Unidade de Diabetes, follow-up, he showed abnormal fasting glucose (113 mg/dL), increased level of HbA1c (6.6%), and Hospital das Clínicas, FMUSP, negative β-cell antibodies. His father and two siblings also had slightly elevated blood glucose le- São Paulo, SP, Brazil vels. The mother had normal glycemia. A GCK heterozygous missense mutation, p.Arg191Trp, was identified in the proband. Eighteen family members were screened for this mutation, and 11 had the mutation in heterozygous state. Case 2: a 4-year-old boy investigated for short stature revealed no other laboratorial alterations than elevated glycemia (118 mg/dL); β-cell antibodies were nega- tive.
  • Mat Kadi Tora Tutti O Al Ut Hit Hitta Atuh

    Mat Kadi Tora Tutti O Al Ut Hit Hitta Atuh

    MAT KADI TORA TUTTI USO AL20180235194A1 UT HIT HITTA ATUH ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0235194 A1 Fahrenkrug et al. (43 ) Pub . Date : Aug . 23, 2018 ( 54 ) MULTIPLEX GENE EDITING Publication Classification (51 ) Int. Ci. ( 71 ) Applicant: Recombinetics , Inc ., Saint Paul, MN A01K 67/ 027 (2006 . 01 ) (US ) C12N 15 / 90 ( 2006 .01 ) (72 ) Inventors : Scott C . Fahrenkrug, Minneapolis , (52 ) U . S . CI. MN (US ) ; Daniel F . Carlson , CPC .. .. A01K 67 / 0276 (2013 . 01 ) ; C12N 15 / 907 Woodbury , MN (US ) ( 2013 .01 ) ; A01K 67 /0275 ( 2013 .01 ) ; A01K 2267/ 02 (2013 .01 ) ; AOIK 2217 / 15 (2013 .01 ) ; AOIK 2227 / 108 ( 2013 .01 ) ; AOIK 2217 /07 (21 ) Appl. No. : 15 /923 , 951 ( 2013 .01 ) ; A01K 2227/ 101 (2013 .01 ) ; AOIK ( 22 ) Filed : Mar. 16 , 2018 2217 /075 ( 2013 .01 ) (57 ) ABSTRACT Related U . S . Application Data Materials and methods for making multiplex gene edits in (62 ) Division of application No . 14 /698 ,561 , filed on Apr. cells and are presented . Further methods include animals 28 , 2015, now abandoned . and methods of making the same . Methods of making ( 60 ) Provisional application No . 61/ 985, 327, filed on Apr. chimeric animals are presented , as well as chimeric animals . 28 , 2014 . Specification includes a Sequence Listing . Patent Application Publication Aug . 23 , 2018 Sheet 1 of 13 US 2018 / 0235194 A1 GENERATION OF HOMOZYGOUS CATTLE EDITED AT ONE ALLELE USING SINGLE EDITS Edit allele , Raise FO to Mate FO enough times Raise F1s to Mate F1 siblings Clone cell , sexual maturity , to produce enough F1 sexualmaturity , to make Implant, Gestate 2 years generation carrying 2 years homozygous KO , 9 months , birth edited allele to mate 9 months of FO with each other Generation Primary Fibroblasts ? ? ? Time, years FIG .
  • BY Aaron J. Gottschalk

    BY Aaron J. Gottschalk

    BIOCHEMICAL AND DEVELOPMENTAL CHARACTERIZATION OF A SNF2-LIKE ATPASE AMPLIFIED IN LIVER CANCER 1 (ALC1) BY Aaron J. Gottschalk Submitted to the graduate degree program in Biochemistry and Molecular Biology and the Graduate faculty of the University of Kansas Medical Center in partial fulfillment for the degree of Doctor of Philosophy. _______________________ Chairperson Committee members* _______________________* _______________________* _______________________* _______________________* Date defended: ________________ The Dissertation Committee for Aaron J. Gottschalk certifies that this is the approved version of the following dissertation: BIOCHEMICAL AND DEVELOPMENTAL CHARACTERIZATION OF A SNF2-LIKE ATPASE AMPLIFIED IN LIVER CANCER 1 (ALC1) Committee: _______________________ Chairperson* _______________________ _______________________ _______________________ _______________________ Date defended: ________________ 2 ACKNOWLEDGEMENTS First and foremost, I would like to express my deepest thanks and gratitude to my mentors Joan and Ron Conaway. During my tenure in their lab as a graduate student I have been afforded an amazing opportunity to learn and grow as a scientist while independently developing this project. It is their extreme kindness, steadfast encouragement, guidance, and humor that have made even the toughest of problems both scientific and in life seem very surmountable, and for that I thank them profoundly. Next, I would like to thank my committee members Drs. Glen Andrews, Jennifer Gerton, Leslie Heckert, and Ken Peterson for all their useful advice and suggestions throughout the course of my graduate career. Not only did my committee members provide great scientific direction but they also made bi-annual meetings fun and engaging. I would like to thank all of the members of the Conaway Lab including: Charles Banks, Margaret Banks, Yong Cai, Jingji Jin, Stephanie Kong, Nawel Mahrour, Ana Pedraza, Chieri Sato, Shigeo Sato, Henrietta Szutorisz, Hide Takahashi, Tingting Yao, Dotan Sela, Lu Chen, and Merry McClaird.
  • PMC5805680.Pdf

    PMC5805680.Pdf

    ARTICLE DOI: 10.1038/s41467-018-02942-5 OPEN Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer Alison P. Klein et al.# In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European 1234567890():,; ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10−8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PAN- DoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10−14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10−10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10−8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10−8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quan- titative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene. Correspondence and requests for materials should be addressed to A.P.K. (email: [email protected]) or to L.T.A. (email: [email protected]) #A full list of authors and their affliations appears at the end of the paper. NATURE COMMUNICATIONS | (2018) 9:556 | DOI:
  • Of Analyses January 2019 Imprint

    Of Analyses January 2019 Imprint

    Index of Analyses January 2019 Imprint We reserve the right for errors and alterations. Our laboratory is part of the SYNLAB group. © 3rd edition By SYNLAB Medizinisches Versorgungszentrum Humane Genetik Medical Practice and Laboratory for Human genetics 2 Medical Director Dr. med. Dr. rer. nat. Claudia Nevinny-Stickel-Hinzpeter Consultant Human geneticist Postal Address Lindwurmstrasse 23 D-80337 Munich / Germany Telephone and Fax Reception +49 (0)89. 54 86 29 -0 Invoicing -0 Fax -243 Molecular Genetics -554 Cytogenetics -559 Office hours Monday – Friday 8.30 – 18.00 [email protected] www.humane-genetik.de 3 Table of contents Preanalytics 5 Molecular genetic analyses 8 Cardiac diseases 8 Complex syndromes 13 Connective Tissue Disorders 23 Endocrinology 26 Eye diseases 29 Fertility disorders 30 Gastrointestinal diseases 32 Hematology 33 Hemophilia 35 Hereditary cancer syndromes 36 Immune disorders 44 Intersexuality 45 Kidney diseases 46 Liver diseases 48 Lung diseases 50 Metabolic diseases 51 Mitochondrial diseases 61 Neurodegenerative diseases 64 Neuromuscular diseases /Neuropathies 69 Nutrigenetics 74 Pancreatic diseases 75 Periodic fever 76 Pharmacogenetics 80 Short stature 82 Thrombophilia/Atherosclerosis 84 Uniparental disomies 90 Kinship Analyses 91 Cytogenetics and molecular cytogenetics 92 Prenatal chromosome diagnostics 92 Postnatal chromosome diagnostics 94 Molecular cytogenetics 96 Chromosomal microarray diagnostics 99 Quality assurance 100 Index 104 Index gene names 116 4 Preanalytics Testing Material For genetic testing nuclei-containing cells of the patient are required, which are either cultivated or subjected to DNA extraction. Cells can be harvested from peripheral blood, buccal swabs, amniotic fluid, chorionic villi (CVS), or tissue samples. In case of blood collection, no special preparation of the patient, e.g.
  • At the Staff Meeting of the Department of Pediatrics №4

    At the Staff Meeting of the Department of Pediatrics №4

    Ministry of Health of Ukraine Bogomolets National Medical University “APPROVED” At the staff meeting of the Department of pediatrics №4 Chief of the Department of Pediatrics №4 Academician, Professor, MD, PhD Maidannyk V.G. __________________________(Signature) “_____” ___________________ 2020 y. Methodological recommendations for students Subject Pediatrics, Children’s infectious diseases. Module 1 Pediatrics Topic Thyroid gland diseases in children. Course 5 Faculty Medical №2 Kyiv -2020 1 AUTHORSHIP Head of the Department - Doctor of Medical Sciences, MD, PhD, Academician of the NAMS of Ukraine Professor V.G. Maidannyk; MD, PhD, Associate Professor Ie.A. Burlaka; MD, PhD, Associate Professor R.V. Terletskiy; MD, PhD, Associate Professor O.S. Kachalova O.S.; MD, PhD Assistant T.D. Klets; MD, PhD Assistant T.A. Shevchenko. Topic: Thyroid gland diseases in children. Classification of thyroid diseases in children. Etiology, pathogenesis, clinical presentation, diagnostics, differential diagnostics, treatment, prophylaxis of diffuse toxic goiter, hypothyroidism, autoimmune thyroiditis, Prognosis. І. Topic Relevance. Thyroid functions disturbances is the common state among children. Thyroid diseases is quite various in children age. Thyroid diseases problems are the main relating to Chernobyl disaster because of morbidity increasing among children in autoimmune thyroiditis, hypothyroidism, good- quality and malignant tumors of thyroid. One of major places occupies congenital hypothyroidism that meets in frequency of 1 case to 5000 newborns. Congenital hypothyroidism in 85 – 90% of cases is primary and related to the iodine deficit or thyroid dysgenesis. Thus, the aplasia, hypogenesis or dystopia of thyroid are the more frequent states. Primary hypothyroidism in 5 – 10% of cases unconditioned by dyshormonose (autosomal – recessive inheritance).
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0186168 A1 Konieczka Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0186168 A1 Konieczka Et Al

    US 2016O1861 68A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0186168 A1 Konieczka et al. (43) Pub. Date: Jun. 30, 2016 (54) PROCESSES AND HOST CELLS FOR Related U.S. Application Data GENOME, PATHWAY. AND BIOMOLECULAR (60) Provisional application No. 61/938,933, filed on Feb. ENGINEERING 12, 2014, provisional application No. 61/935,265, - - - filed on Feb. 3, 2014, provisional application No. (71) Applicant: ENEVOLV, INC., Cambridge, MA (US) 61/883,131, filed on Sep. 26, 2013, provisional appli (72) Inventors: Jay H. Konieczka, Cambridge, MA cation No. 61/861,805, filed on Aug. 2, 2013. (US); James E. Spoonamore, Publication Classification Cambridge, MA (US); Ilan N. Wapinski, Cambridge, MA (US); (51) Int. Cl. Farren J. Isaacs, Cambridge, MA (US); CI2N 5/10 (2006.01) Gregory B. Foley, Cambridge, MA (US) CI2N 15/70 (2006.01) CI2N 5/8 (2006.01) (21) Appl. No.: 14/909, 184 (52) U.S. Cl. 1-1. CPC ............ CI2N 15/1082 (2013.01); C12N 15/81 (22) PCT Filed: Aug. 4, 2014 (2013.01); C12N 15/70 (2013.01) (86). PCT No.: PCT/US1.4/49649 (57) ABSTRACT S371 (c)(1), The present disclosure provides compositions and methods (2) Date: Feb. 1, 2016 for genomic engineering. Patent Application Publication Jun. 30, 2016 Sheet 1 of 4 US 2016/O186168 A1 Patent Application Publication Jun. 30, 2016 Sheet 2 of 4 US 2016/O186168 A1 &&&&3&&3&&**??*,º**)..,.: ××××××××××××××××××××-************************** Patent Application Publication Jun. 30, 2016 Sheet 3 of 4 US 2016/O186168 A1 No.vaegwzºkgwaewaeg Patent Application Publication Jun. 30, 2016 Sheet 4 of 4 US 2016/O186168 A1 US 2016/01 86168 A1 Jun.
  • Endocrine Test Selection and Interpretation

    Endocrine Test Selection and Interpretation

    The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition Edited by: Delbert A. Fisher, MD Senior Science Officer Quest Diagnostics Nichols Institute Professor Emeritus, Pediatrics and Medicine UCLA School of Medicine Consulting Editors: Wael Salameh, MD, FACP Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute San Juan Capistrano, CA Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Richard W. Furlanetto, MD, PhD Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute Chantilly, VA ©2007 Quest Diagnostics Incorporated. All rights reserved. Fourth Edition Printed in the United States of America Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. All third party marks − ®' and ™' − are the property of their respective owners. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, and information storage and retrieval system, without permission in writing from the publisher. Address inquiries to the Medical Information Department, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130. Previous editions copyrighted in 1996, 1998, and 2004. Re-order # IG1984 Forward Quest Diagnostics Nichols Institute has been
  • Human Genetics (A-D)

    Human Genetics (A-D)

    Patient’s Name Date of Birth Human Genetics Labor Lademannbogen MVZ GmbH Professor-Rüdiger- Arndt-Haus Tel.: (040) 53805 800 Address Lademannbogen 61-63 Fax: (040) 53805 821 22339 Hamburg www.labor-lademannbogen.de Country - Doctor’s practice stamp - Human Genetics (A-D) Sampling date__________________________________________________________________________________ 1p36 deletion syndrome Hep CADASIL (NOTCH3) E 3-beta-HSD deficiency (HSD3B2) E Cardiomyopathy, dilatative E 5-fluorouracil toxicity (DPD deficiency) E Cardiomyopathy, hypertrophic E Aarskog syndrome (Faciogenital dysplasia) E Cardiomyopathy, long-QT E Aceruloplasminemia E Cardiomyopathy, others E Achondroplasia E Carnitine palmitoyltransferase II deficiency E Adiposity, Leptin E Cataract (EPHA2, GALK) E Adiposity, Leptin Receptor E CDG syndrome, CDG 1a (PMM2) E Adiposity, Melanocortin 4 Receptor E CDG syndrome, CDG 1b (MPI) E Adiposity, Proopiomelanocortin E CDG syndrome, CDG 1c (ALG6) E Adiposity, Proproteinconvertase E CDG syndrome, CDG 2c (SLC35C1) E Agammaglobulinemia, X-linked (BTK) E Cholestasis, intrahepatic, benign recurrent (BRIC) E Aicardi-Goutières syndrome E Cholestasis, intrahepatic, of pregnancy (ICP) E AIRE (APECED) E Cholestasis, intrahepatic, progressive familial (PFIC) E Alagille syndrome (JAG1) E Chromosomal diagnosis of leukemia and lymphoma BM etc. Albright osteodystrophy (GNAS1) E Chromosomal diagnosis of spontaneous abortions CVS Alpers syndrome (POLG1) E Chromosomal diagnosis, postnatal Hep Alpha 1 antitrypsin genotyping
  • Neonatal Diabetes and MODY Information Sheet 6-14-19

    Neonatal Diabetes and MODY Information Sheet 6-14-19

    Next Generation Sequencing Panels for Neonatal Diabetes Mellitus (NDM) and Maturity-Onset Diabetes of the Young (MODY) Monogenic diabetes mellitus includes a heterogeneous group of diabetes types that are caused by mutations in single genes. It is estimated that the monogenic forms of diabetes could represent as much as 1–2% of all cases of diabetes mellitus 1. The main phenotypes suggestive of an underlying monogenic cause include neonatal diabetes mellitus (NDM), maturity-onset diabetes of the young (MODY) and very rare diabetes-associated syndromes. Neonatal Diabetes Mellitus (NDM) is diabetes diagnosed within the first 6 months of life and can be characterized as either permanent (PNDM), requiring lifelong treatment, or transient (TNDM), which typically resolves by 18 months of age. NDM is rare with an incidence of approximately 1:1,000,000-260,000 live births. Maturity-onset diabetes of the young (MODY) is more common than NDM and usually occurs in children or adolescents but may be mild and not detected until adulthood. It is predicted that MODY accounts for approximately 1-2% of all Diabetes cases with an incidence of approximately 100 cases per million in the UK population. Approximately thirty genes that are highly expressed in the pancreatic beta-cell have been identified in these monogenic subtypes of diabetes, and many other genes have been implicated in syndromes that often include diabetes. Several etiological mechanisms of beta-cell dysfunction are involved including reduced beta-cell number, failure of glucose sensing and increased destruction of the beta-cell, which result in inadequate insulin secretion despite chronic hyperglycemia 2-4.